Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline

Tarsus Pharmaceuticals closed its acquisition of iRenix Medical, adding IRX-101 to its pipeline and giving the company its first strategic position in the retina market.

The deal expands Tarsus beyond its core eye-care focus. IRX-101 is designed to replace povidone-iodine for patients receiving repeated intravitreal injections, aiming to reduce pain, irritation and ocular surface damage. In a Phase IIb/III study, it showed statistically significant improvements versus povidone-iodine, including less pain and less corneal staining.

Tarsus plans to start a pivotal Phase III COMFORT study in the first half of 2027, with top-line data expected in 2028. The acquisition cost was about $75 million upfront, with up to $490 million in milestones and royalties possible if the drug succeeds.

Tarsus Pharmaceuticals NASDAQ: TARS said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company seeks to expand its presence in eye care and enter the retina market.

On an investor call discussing the deal, Bobby Azamian, Tarsus’ chief executive officer and chairman, said the acquisition represents “the next step in expanding our pipeline” and establishes the company’s first strategic position in retina. He said IRX-101 is aimed at improving the experience for patients who undergo repeated intravitreal injections, which are commonly used in retinal disease treatment.

Tarsus executives said more than 11 million intravitreal injections are performed annually in the United States, with many patients returning every four to eight weeks for years to...